Our interest in KIF20B was piqued when we discovered that it was a target autoantigen in up to 25% of patients with idiopathic ataxia and in some patients with demyelinating polyneuropathy.(12,15) Given the importance of KIF20B in neural development, it is interesting to consider that these antibodies may be biomarkers for ataxia and/or other neuropathies. Here, KIF20B is linked to demyelinating polyneuropathy.